Kymera Therapeutics annual net income
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Net Income Growth & History (KYMR)
Kymera Therapeutics's net income was −$311.4M for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$311.4M | −$87.5M | — |
| 2024 | 2024-12-31 | −$223.9M | −$76.9M | — |
| 2023 | 2023-12-31 | −$147.0M | $7.8M | — |
| 2022 | 2022-12-31 | −$154.8M | −$54.6M | — |
| 2021 | 2021-12-31 | −$100.2M | −$54.6M | — |
| 2020 | 2020-12-31 | −$45.6M | −$4.3M | — |
| 2019 | 2019-12-31 | −$41.2M | — | — |
Kymera Therapeutics quarterly net income
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$61.2M | $15.4M | — |
| Q1 2026 | 2026-03-31 | −$69.2M | −$3.7M | — |
| Q4 2025 | 2025-12-31 | −$87.0M | −$16.2M | — |
| Q3 2025 | 2025-09-30 | −$82.2M | −$19.7M | — |
| Q2 2025 | 2025-06-30 | −$76.6M | −$34.6M | — |
| Q1 2025 | 2025-03-31 | −$65.6M | −$17.0M | — |
| Q4 2024 | 2024-12-31 | −$70.8M | −$56.4M | — |
| Q3 2024 | 2024-09-30 | −$62.5M | −$9.6M | — |
| Q2 2024 | 2024-06-30 | −$42.1M | −$3.3M | — |
| Q1 2024 | 2024-03-31 | −$48.6M | −$7.6M | — |
| Q4 2023 | 2023-12-31 | −$14.4M | $20.5M | — |
| Q3 2023 | 2023-09-30 | −$52.9M | −$9.9M | — |
| Q2 2023 | 2023-06-30 | −$38.8M | $1.5M | — |
| Q1 2023 | 2023-03-31 | −$40.9M | −$4.2M | — |
| Q4 2022 | 2022-12-31 | −$34.9M | −$965,000 | — |
| Q3 2022 | 2022-09-30 | −$43.0M | −$14.4M | — |
| Q2 2022 | 2022-06-30 | −$40.3M | −$15.6M | — |
| Q1 2022 | 2022-03-31 | −$36.7M | −$23.6M | — |
| Q4 2021 | 2021-12-31 | −$33.9M | −$21.2M | — |
| Q3 2021 | 2021-09-30 | −$28.6M | −$20.6M | — |
| Q2 2021 | 2021-06-30 | −$24.7M | −$10.7M | — |
| Q1 2021 | 2021-03-31 | −$13.1M | −$2.1M | — |
| Q4 2020 | 2020-12-31 | −$12.7M | — | — |
| Q3 2020 | 2020-09-30 | −$8.0M | $3.4M | — |
| Q2 2020 | 2020-06-30 | −$14.0M | — | — |
| Q1 2020 | 2020-03-31 | −$10.9M | — | — |
| Q3 2019 | 2019-09-30 | −$11.4M | — | — |
Kymera Therapeutics net income trends
Over the last five fiscal years, Kymera Therapeutics's net income decreased from −$45.6M to −$311.4M, a change of −$265.8M. The latest reported quarter, Q2 2026, shows −$61.2M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗Community posts
Kymera reports early human results for oral IRF5 drug
Kymera ($KYMR) reported results from its first human study of KT-579, an experimental oral medicine targeting the immune regulator IRF5. In healthy volunteers receiving repeated doses, median blood IRF5 reductions reached at least 90% acros ...
